English
Insider transactions
EDGARPDS BIOTECHNOLOGY CORPORATION
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-17.
- Open-market purchases (code P)
- 0 transactions, — shares
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–14 of 14
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-18 Filed 2026-10-21 | Dawson John Andrew Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 22,700 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 22,700 | Direct (D) | No | F1
| Open filing 0001140361-26-040424 Read from the filing’s XML Dispute this row |
| 2026-10-18 Filed 2026-10-20 | Ramsdell Deborah Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 22,700 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 22,700 | Direct (D) | No | F1
| Open filing 0001140361-26-040294 Read from the filing’s XML Dispute this row |
| 2026-10-18 Filed 2026-10-20 | Wendel Bruce Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 22,700 | 0.00 | 0Derived: shares × price per share. Exact value 0.00. | 22,700 | Direct (D) | No | F1
| Open filing 0001140361-26-040292 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Boesgaard Lars Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001140361-26-007646 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Toutain Stephan Officer: Chief Operating Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001140361-26-007644 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | BRAWLEY OTIS W Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,876 | 0 | — | 54,876 | Direct (D) | No | F1
| Open filing 0001140361-26-007640 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | BEDU-ADDO FRANK Director · Officer: President/CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 548,782 | 0 | — | 548,782 | Direct (D) | No | F1
| Open filing 0001140361-26-007649 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Shepard Kirk V. Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001140361-26-007647 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | CONN GREGORY Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 150,000 | 0 | — | 150,000 | Direct (D) | No | F1
| Open filing 0001140361-26-007648 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Iliev Ilian Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,876 | 0 | — | 54,876 | Direct (D) | No | F1
| Open filing 0001140361-26-007642 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Glover Stephen C. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,876 | 0 | — | 54,876 | Direct (D) | No | F1
| Open filing 0001140361-26-007639 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Brown Spencer D. Officer: Senior VP, General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 300,000 | 0 | — | 300,000 | Direct (D) | No | F1
| Open filing 0001140361-26-007645 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Ali-Jackson Kamil Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,876 | 0 | — | 54,876 | Direct (D) | No | F1
| Open filing 0001140361-26-007641 Read from the filing’s XML Dispute this row |
| 2026-01-12 Filed 2026-03-03 | Freitag Gregory Gene Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,876 | 0 | — | 54,876 | Direct (D) | No | F1
| Open filing 0001140361-26-007643 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Nant Capital, LLC Common Stock, par value $0.00033 per share | 19.9 | 22,856,453.00 | 11/09/2026 Filed 2026-11-12 | SCHEDULE 13D/AAmendment 1 | Open filing 0001193125-26-456632 Dispute this row |
| Patrick Soon-Shiong Common Stock, par value $0.00033 per share | 19.9 | 22,856,453.00 | 11/09/2026 Filed 2026-11-12 | SCHEDULE 13D/AAmendment 1 | Open filing 0001193125-26-456632 Dispute this row |
| Nant Capital, LLC Common Stock, par value $0.00033 per share | 19.9 | 20,336,335 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13D | Open filing 0001193125-26-397073 Dispute this row |
| Patrick Soon-Shiong Common Stock, par value $0.00033 per share | 19.9 | 20,336,335 | 09/14/2026 Filed 2026-09-21 | SCHEDULE 13D | Open filing 0001193125-26-397073 Dispute this row |
| Armistice Capital, LLC Common Stock, par value $0.00033 per share | 4.99 | 2,283,288.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-25-003567 Dispute this row |
| Steven Boyd Common Stock, par value $0.00033 per share | 4.99 | 2,283,288.00 | 06/30/2025 Filed 2025-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-25-003567 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,137,454 filings read, dated 2004-06-14 to 2026-11-16: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 1 |
| 2016 | 204,322 |
| 2017 | 202,494 |
| 2018 | 202,048 |
| 2019 | 193,638 |
| 2020 | 144,184 |
| 2021 | 224,474 |
| 2022 | 60,488 |
| 2023 | 199,811 |
| 2024 | 209,823 |
| 2025 | 235,520 |
| 2026 | 254,873 |
Filings made before the SEC required XML are listed, not extracted.